Norveška - norveški - Statens legemiddelverk

consilient health limited - kolekalsiferol - kapsel, myk - 25000 iu

Norveška - norveški - Statens legemiddelverk

consilient health limited - kolekalsiferol - kapsel, myk - 50000 iu

Norveška - norveški - Statens legemiddelverk

bristol-myers squibb ab - triamcinolonacetonid - injeksjonsvæske, suspensjon - 40 mg/ ml

Norveška - norveški - Statens legemiddelverk

takeda pharmaceuticals international ag ireland branch - mesalazin - enterodepottablett - 1200 mg

Norveška - norveški - Statens legemiddelverk

aspen pharma trading limited - mivakuriumklorid - injeksjonsvæske, oppløsning - 2 mg/ ml

Norveška - norveški - Statens legemiddelverk

aspen pharma trading limited - remifentanilhydroklorid - pulver til injeksjons-/infusjonsvæske, oppløsning - 2 mg

Norveška - norveški - Statens legemiddelverk

aspen pharma trading limited - remifentanilhydroklorid - pulver til injeksjons-/infusjonsvæske, oppløsning - 1 mg

Norveška - norveški - Statens legemiddelverk

aspen pharma trading limited - remifentanilhydroklorid - pulver til injeksjons-/infusjonsvæske, oppløsning - 5 mg

Norveška - norveški - Statens legemiddelverk

consilient health limited - kalsiumkarbonat / kolekalsiferol - tyggetablett med appelsinsmak - 500 mg / 800 iu

Europska Unija - norveški - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - ozanimod hydrochloride - multiple sclerosis, relapsing-remitting; colitis, ulcerative - immunsuppressive - multiple sclerosiszeposia is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis (rrms) with active disease as defined by clinical or imaging features. ulcerative colitiszeposia is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis (uc) who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic agent.